IL273725A - Peptides from Apanniadam10, preparations containing them and their uses - Google Patents

Peptides from Apanniadam10, preparations containing them and their uses

Info

Publication number
IL273725A
IL273725A IL273725A IL27372520A IL273725A IL 273725 A IL273725 A IL 273725A IL 273725 A IL273725 A IL 273725A IL 27372520 A IL27372520 A IL 27372520A IL 273725 A IL273725 A IL 273725A
Authority
IL
Israel
Prior art keywords
adam10
compositions
same
modulating peptides
peptides
Prior art date
Application number
IL273725A
Other languages
English (en)
Hebrew (he)
Original Assignee
Verra Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Verra Therapeutics filed Critical Verra Therapeutics
Publication of IL273725A publication Critical patent/IL273725A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24Metalloendopeptidases (3.4.24)
    • C12Y304/24081ADAM10 endopeptidase (3.4.24.81)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886Metalloendopeptidases (3.4.24), e.g. collagenase
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489Metalloendopeptidases (3.4.24)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
IL273725A 2017-10-02 2020-03-31 Peptides from Apanniadam10, preparations containing them and their uses IL273725A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762566580P 2017-10-02 2017-10-02
US201762589842P 2017-11-22 2017-11-22
PCT/US2018/053938 WO2019070685A1 (en) 2017-10-02 2018-10-02 METHODS AND COMPOSITIONS FOR INHIBITING BIOLOGICAL ACTIVITIES OF ADAM10

Publications (1)

Publication Number Publication Date
IL273725A true IL273725A (en) 2020-05-31

Family

ID=65995419

Family Applications (1)

Application Number Title Priority Date Filing Date
IL273725A IL273725A (en) 2017-10-02 2020-03-31 Peptides from Apanniadam10, preparations containing them and their uses

Country Status (8)

Country Link
US (3) US20190345473A1 (enExample)
EP (1) EP3691671A4 (enExample)
JP (2) JP7448219B2 (enExample)
AU (1) AU2018345601B2 (enExample)
CA (1) CA3077694A1 (enExample)
IL (1) IL273725A (enExample)
MX (1) MX2020004218A (enExample)
WO (1) WO2019070685A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12247232B2 (en) 2018-01-31 2025-03-11 Verra Therapeutics, Inc. Methods and compositions for inhibiting ADAM 9 biological activities
WO2020227714A1 (en) * 2019-05-09 2020-11-12 Verra Therapeutics, Llc Methods and compositions for inhibiting adam8 biological activities
US20250177333A1 (en) * 2022-03-08 2025-06-05 Nova Southeastern University Method for treating rheumatoid arthritis (ra) using an enzyme-and substrate selective exosite inhibitor of a disintegrin and metalloprotease 10 (adam10)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003270625A1 (en) 2002-09-11 2004-04-30 Justus-Liebig-Universität Giessen Inhibition or activation of adam9 and adam15 for treatment of vascularization-related disease and wound healing
CA2525574C (en) * 2003-05-15 2015-06-30 Trustees Of Tufts College Stable analogs of peptide and polypeptide therapeutics
KR101317358B1 (ko) 2005-02-02 2013-10-15 레이븐 바이오테크놀로지스, 인코퍼레이티드 Adam-9 조절자
CA2604883A1 (en) 2005-04-07 2006-10-19 Albert Lai Adam10 in cancer diagnosis, detection and treatment
US7638301B2 (en) * 2006-08-28 2009-12-29 Biozyme, Inc. Prodomain modulators of ADAM 10
US20090285840A1 (en) 2008-04-29 2009-11-19 New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery Methods for treating pathological neovascularization
US8079782B1 (en) 2008-05-16 2011-12-20 Hilfiker William K Semi-extensible steel soil reinforcements for mechanically stabilized embankments
EP2637679A4 (en) * 2010-11-09 2015-09-23 Univ Chicago ROLE OF ADAM10 AND ITS RELEVANCE TO DISEASES AND THERAPEUTICS
WO2012088105A2 (en) * 2010-12-20 2012-06-28 Biozyme Inc. Methods and compositions for predicting disease status in cancer
WO2015117199A1 (en) 2014-02-04 2015-08-13 Monash University Anti-metalloprotease antibody for diagnosis and treatment of cancers

Also Published As

Publication number Publication date
US20190345473A1 (en) 2019-11-14
US12297469B2 (en) 2025-05-13
MX2020004218A (es) 2020-11-11
US20230203468A1 (en) 2023-06-29
EP3691671A4 (en) 2022-01-19
JP2024012470A (ja) 2024-01-30
AU2018345601A1 (en) 2020-05-21
AU2018345601B2 (en) 2025-05-15
JP7448219B2 (ja) 2024-03-12
CA3077694A1 (en) 2019-04-11
WO2019070685A1 (en) 2019-04-11
US20250207119A1 (en) 2025-06-26
JP2021500321A (ja) 2021-01-07
EP3691671A1 (en) 2020-08-12

Similar Documents

Publication Publication Date Title
IL274297A (en) Pyrazolo-piperidine-converted indole-2-carboxamides, preparations containing them and their uses
IL268588A (en) Anti-gprc5d antibodies, compositions comprising same and uses thereof
IL283754A (en) Anti-claudin antibodies, preparations containing them and their uses
PL3668937T3 (pl) Kompozycje i zastosowania Z-1-chloro-2,3,3,3-tetrafluoroprop-1-enu
IL271275A (en) Preparations containing coronas and their uses
IL307791B2 (en) Recombinant virus, preparations containing it and its uses
EP3290434A4 (en) Peptide having anti-diabetic and anti-obesity effects, and use thereof
EP3347472A4 (en) COMPOSITIONS WITH CYP76AD1 CLADE POLYPEPTIDES AND USES THEREOF
IL247221B (en) Antibodies that bind to the dengue virus, preparations containing them and their uses
FR3021319B1 (fr) Peptides, compositions les comprenant et utilisations notamment cosmetiques
IL265796A (en) Preparations comprising short peptides derived from pedf and their uses
IL246987A0 (en) Heteroaryl amides, preparations containing it and their uses
EP3263122A4 (en) Peptide for preventing hearing loss, and composition comprising same
IL272055A (en) 8,1-naphthyridinone compounds and their uses
EP3642219A4 (en) PEPTIDE COMPOSITIONS AND RELATED PROCEDURES
SG11202006669RA (en) Peptides and uses thereof
GB2576614B (en) Compositions, uses and methods
EP3265472A4 (en) Cytotoxic hexim1 peptides and uses thereof
IL273725A (en) Peptides from Apanniadam10, preparations containing them and their uses
IL272834A (en) Compositions of amantadine, their preparation, and methods of use
GB201804163D0 (en) Uses, compositions and methods
IL270917A (en) Recombinant ROBO2 proteins, preparations, methods and their use
IL273063A (en) Peptides inhibiting klk1, klk4, or klk4 and klk8, compositions comprising same and uses thereof
EP3706799B8 (en) Peptide for preventing, modulating and/or reducing cardiovascular disease
EP3650464B8 (en) Peptide compound and application thereof, and composition containing peptide compound